
    
      It will be conducted to assess the pharmacokinetics of OXN 5/2.5 and OXN 20/10 tablets.
      Subjects will be allocated to a sequence of two strength group in accordance with a random
      allocation schedule (RAS) in a 1:1 ratio.

      Subjects will attend a screening visit within 14 days of the first (OXN) dosing day (Day 1).

      Eligible subjects will then check into the study unit on the day before OXN dosing (Day -2).
      Subjects will be administered their OXN dose the next 2 morning (Day 1), following an
      overnight fast.
    
  